Choline Chloride for Injection + Placebo
Phase 2/3Recruiting 0 watching 0 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Choline Deficiency
Conditions
Choline Deficiency, Liver Injury
Trial Timeline
Dec 10, 2025 → Jun 1, 2028
NCT ID
NCT06910943About Choline Chloride for Injection + Placebo
Choline Chloride for Injection + Placebo is a phase 2/3 stage product being developed by Protara Therapeutics for Choline Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06910943. Target conditions include Choline Deficiency, Liver Injury.
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06910943 | Phase 2/3 | Recruiting |
Competing Products
2 competing products in Choline Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD8848 | AstraZeneca | Phase 1 | 33 |
| Dupilumab + Placebo | Sanofi | Phase 2 | 51 |